Richard Whitley to Virus Replication
This is a "connection" page, showing publications Richard Whitley has written about Virus Replication.
Connection Strength
1.491
-
Sorivudine: a potent inhibitor of varicella zoster virus replication. Adv Exp Med Biol. 1996; 394:41-4.
Score: 0.123
-
Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One. 2013; 8(11):e81768.
Score: 0.106
-
An inquiry into the molecular basis of HSV latency and reactivation. Annu Rev Microbiol. 2013; 67:355-74.
Score: 0.100
-
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol. 2012 May; 86(9):5304-13.
Score: 0.094
-
Current management and recommendations for access to antiviral therapy of herpes labialis. J Clin Virol. 2012 Jan; 53(1):6-11.
Score: 0.091
-
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob Agents Chemother. 2009 Dec; 53(12):5251-8.
Score: 0.079
-
Effect of recombinant hybrid human interferon on replication and morphogenesis of HSV-1 in monkey cells. Virus Res. 1989 Jan; 12(1):33-41.
Score: 0.076
-
HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice. Vaccine. 2007 Sep 17; 25(37-38):6764-73.
Score: 0.068
-
Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus. J Virol. 1985 Nov; 56(2):419-25.
Score: 0.061
-
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine. 2006 Mar 06; 24(10):1644-52.
Score: 0.060
-
Human herpesvirus 6 infection of the central nervous system: is it just a case of mistaken association? Clin Infect Dis. 2005 Mar 15; 40(6):894-5.
Score: 0.058
-
Lessons from HIV and hepatitis viruses. Antiviral Res. 2004 Aug; 63 Suppl 1:S11-8.
Score: 0.056
-
Herpes simplex virus infection. Semin Pediatr Infect Dis. 2002 Jan; 13(1):6-11.
Score: 0.046
-
Herpes simplex virus infections. Lancet. 2001 May 12; 357(9267):1513-8.
Score: 0.044
-
Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. Hum Gene Ther. 2020 10; 31(19-20):1132-1139.
Score: 0.042
-
Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res. 1998 Dec; 40(1-2):73-84.
Score: 0.038
-
Herpes simplex viruses. Clin Infect Dis. 1998 Mar; 26(3):541-53; quiz 554-5.
Score: 0.036
-
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997 Apr 15; 57(8):1502-9.
Score: 0.034
-
Differential effect of recombinant human and mouse interferons on replication of herpes simplex virus type 1 in mouse cells. Antiviral Res. 1996 Aug; 32(1):27-34.
Score: 0.032
-
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A. 1995 Feb 28; 92(5):1411-5.
Score: 0.029
-
Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev. 2014 Mar; 25(1):16-27.
Score: 0.027
-
A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014 May; 22(5):1048-55.
Score: 0.027
-
Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest. 1993 Jun; 91(6):2837-43.
Score: 0.026
-
Effect of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine on the replication and morphogenesis of herpes simplex virus type 1. Antiviral Res. 1992 Sep; 19(3):181-92.
Score: 0.024
-
Expression of HSV-1 glycoproteins in tunicamycin-treated monkey kidney cells. Biochem Biophys Res Commun. 1990 Mar 30; 167(3):1139-45.
Score: 0.021
-
Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009 Jan; 17(1):199-207.
Score: 0.019
-
Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J Virol. 2006 Aug; 80(15):7308-15.
Score: 0.016
-
Effect of cloned human interferons on the replication of and cell fusion induced by herpes simplex virus. Virus Res. 1984 Jan; 1(1):81-7.
Score: 0.013
-
Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect. 2002 Sep; 8(9):551-63.
Score: 0.012
-
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 2002 Jan; 9(1):75-80.
Score: 0.012
-
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999 May 01; 59(9):2055-8.
Score: 0.010
-
A rapid protein A binding radioimmunoassay for the evaluation of antiviral agents. J Virol Methods. 1994 Jul; 48(2-3):273-9.
Score: 0.007
-
Antiviral effect of the extract of culture medium of Lentinus edodes mycelia on the replication of herpes simplex virus type 1. Antiviral Res. 1993 Apr; 20(4):293-303.
Score: 0.006